Fexuprazan for the reducing upper gastrointestinal risk in patients with acute ischemic stroke and gastroesophageal reflux disease
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0008578
- Lead Sponsor
- Yonsei University Yongin Severance Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 50
1) Adults aged 19 or above.
2) Patients admitted within 7 days of symptom onset with acute ischemic stroke confirmed by Brain CT or MRI.
3) Patients receiving anticoagulant therapy.
4) Patients with a Gastroesophageal Reflux Disease Questionnaire (GerdQ) score of 8 or higher at the screening timepoint.
5) Patients receiving Fexuprazan.
6) Individuals who voluntarily provided written consent to participate in this clinical trial.
1) Patients who underwent intravenous thrombolysis and/or endovascular thrombectomy for the treatment of ischemic stroke.
2) Individuals with a history of allergic reactions to Fexuprazan.
3) Patients for whom GerdQ questionnaire administration is not feasible.
4) Pregnant or breastfeeding individuals.
5) Individuals who participated in another drug clinical trial within the past 1 month based on the screening criteria. However, participation is allowed if it was an observational study.
6) Individuals deemed inappropriate for participation in the clinical trial for reasons other than those mentioned above.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gastroesophageal reflux disease questionnaire (GerdQ)
- Secondary Outcome Measures
Name Time Method Clinical event of upper gastrointestinal complications as a complication of gastroesophageal reflux disease.